JP2020532534A - ペプチド接合体、接合プロセス及びそれらの使用 - Google Patents

ペプチド接合体、接合プロセス及びそれらの使用 Download PDF

Info

Publication number
JP2020532534A
JP2020532534A JP2020512441A JP2020512441A JP2020532534A JP 2020532534 A JP2020532534 A JP 2020532534A JP 2020512441 A JP2020512441 A JP 2020512441A JP 2020512441 A JP2020512441 A JP 2020512441A JP 2020532534 A JP2020532534 A JP 2020532534A
Authority
JP
Japan
Prior art keywords
amino acid
peptide
compound
formula
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020512441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532534A5 (cg-RX-API-DMAC7.html
Inventor
アン ブリンブル マーガレット
アン ブリンブル マーガレット
ロードリック ダンバー ピーター
ロードリック ダンバー ピーター
マーティン ウィリアムズ ジェフリー
マーティン ウィリアムズ ジェフリー
バードン ダニエル
バードン ダニエル
Original Assignee
オークランド ユニサービシーズ リミティド
オークランド ユニサービシーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オークランド ユニサービシーズ リミティド, オークランド ユニサービシーズ リミティド filed Critical オークランド ユニサービシーズ リミティド
Publication of JP2020532534A publication Critical patent/JP2020532534A/ja
Publication of JP2020532534A5 publication Critical patent/JP2020532534A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020512441A 2017-08-30 2018-08-30 ペプチド接合体、接合プロセス及びそれらの使用 Pending JP2020532534A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ73500817 2017-08-30
NZ735008 2017-08-30
PCT/IB2018/056611 WO2019043604A1 (en) 2017-08-30 2018-08-30 PEPTIDE CONJUGATES, CONJUGATION METHOD, AND USES THEREOF

Publications (2)

Publication Number Publication Date
JP2020532534A true JP2020532534A (ja) 2020-11-12
JP2020532534A5 JP2020532534A5 (cg-RX-API-DMAC7.html) 2021-09-30

Family

ID=65526296

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020512441A Pending JP2020532534A (ja) 2017-08-30 2018-08-30 ペプチド接合体、接合プロセス及びそれらの使用

Country Status (14)

Country Link
US (1) US20200361864A1 (cg-RX-API-DMAC7.html)
EP (1) EP3676250A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020532534A (cg-RX-API-DMAC7.html)
KR (1) KR20200058424A (cg-RX-API-DMAC7.html)
CN (1) CN111247123A (cg-RX-API-DMAC7.html)
AU (1) AU2018323043A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020003907A2 (cg-RX-API-DMAC7.html)
CA (1) CA3073314A1 (cg-RX-API-DMAC7.html)
EA (1) EA202090319A1 (cg-RX-API-DMAC7.html)
IL (1) IL272931A (cg-RX-API-DMAC7.html)
MX (1) MX2020002084A (cg-RX-API-DMAC7.html)
SG (1) SG11202001602QA (cg-RX-API-DMAC7.html)
TW (1) TW201925240A (cg-RX-API-DMAC7.html)
WO (1) WO2019043604A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019119067A1 (en) 2017-12-21 2019-06-27 Ena Therapeutics Pty Ltd Optimised compounds
KR20220050873A (ko) * 2019-06-26 2022-04-25 악셀리아 온콜로지 피티와이 리미티드 신규한 분자
CN110681362B (zh) * 2019-09-26 2020-09-11 浙江大学 以羧基和吲哚基为功能基团的混合模式层析介质
CN111349054A (zh) * 2020-01-21 2020-06-30 青岛科技大学 一种防锈剂2-(1,3-苯并噻唑-2-硫基)丁二酸的制备方法
US20230278954A1 (en) * 2020-06-26 2023-09-07 Ena Respiratory Pty Ltd Branched lipid compouds
AU2022338350A1 (en) * 2021-09-02 2024-02-29 Ena Respiratory Pty Ltd Formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012523379A (ja) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
JP2016523891A (ja) * 2013-06-28 2016-08-12 オークランド ユニサービシーズ リミティド アミノ酸及びペプチド接合体及び接合方法
JP2019509280A (ja) * 2016-02-26 2019-04-04 オークランド ユニサービシーズ リミティド アミノ酸及びペプチド接合体及び接合方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1230261B1 (en) * 1999-11-15 2008-06-25 Ludwig Institute For Cancer Research Ny-eso-1 nonapeptide derivatives, and uses thereof
EP2334332A4 (en) * 2008-09-05 2013-01-09 Id Biomedical Corp Quebec NEW COMPOSITIONS AND NEW ADJUVANTS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012523379A (ja) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
JP2016523891A (ja) * 2013-06-28 2016-08-12 オークランド ユニサービシーズ リミティド アミノ酸及びペプチド接合体及び接合方法
JP2019509280A (ja) * 2016-02-26 2019-04-04 オークランド ユニサービシーズ リミティド アミノ酸及びペプチド接合体及び接合方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUR. J. ORG. CHEM. 2016, PP.2608-2616, DOI: 10.1002/EJOC.201501375, JPN6022031415, ISSN: 0004840525 *
MUNEAKI KURINURA: "Structure-activity relationship of lipopeptide from outer membrane of escherichia coli and synthesis", CHEM. PHARM. BULL, vol. 41(3), JPN6021009596, 1993, pages 627 - 629, ISSN: 0004840524 *

Also Published As

Publication number Publication date
CA3073314A1 (en) 2019-03-07
TW201925240A (zh) 2019-07-01
WO2019043604A1 (en) 2019-03-07
EA202090319A1 (ru) 2020-10-16
EP3676250A4 (en) 2021-05-26
CN111247123A (zh) 2020-06-05
IL272931A (en) 2020-04-30
AU2018323043A1 (en) 2020-03-05
EP3676250A1 (en) 2020-07-08
KR20200058424A (ko) 2020-05-27
BR112020003907A2 (pt) 2020-09-08
SG11202001602QA (en) 2020-03-30
MX2020002084A (es) 2020-03-24
US20200361864A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
JP7161404B2 (ja) アミノ酸及びペプチド接合体及び接合方法
JP2020532534A (ja) ペプチド接合体、接合プロセス及びそれらの使用
TWI655201B (zh) 胺基酸及胜肽接合物及結合方法
JP2021073199A (ja) アミノ酸複合体及びペプチド複合体ならびにそれらの使用
HK40013754A (en) Peptides for amino acid and peptide conjugates and conjugation process
HK1224279B (en) Amino acid and peptide conjugates and conjugation process

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230404